Human care company Elekta AB (STO:EKTAB.ST) announced on Monday that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received the CE mark, clearing the technology for commercial sales and clinical use in Europe.

According to the company, Unity has the potential to transform how clinicians treat cancer by enabling the delivery of the radiation dose while simultaneously visualising the tumour and surrounding healthy tissue with high-quality MR images.

Also, Unity integrates advanced tools that allow clinicians to adapt the patient's treatment to this current anatomical information.

Elekta added that although the Unity has CE mark, it is not available for commercial distribution or sale in the US.

Elekta's treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows.